FDA approval for Vaccinia Immune Globulin (VIG) in 32 months, from the time of US Government Contract award. VIG is a critical component for national biodefense programs.

In the event of an emergency, our licensed manufacturing facility allows for readily available surge capacity.

Biodefense contracts with HHS, NIH and CDC in the United States and with Health Canada.

In-house expertise allows for a rapid response to changes throughout the development program.

Cangene has R&D contracts and grants for protein and antibody-based therapies for Burkholderia, Acute Radiation Syndrome, Ebola & Marburg viruses, and Ricin.

Cangene is uniquely positioned for the supply of biodefense products to support the stockpile of programs of governments worldwide.